Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Synthesis of peptides
Reexamination Certificate
2005-02-01
2005-02-01
Carlson, Karen Cochrane (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Synthesis of peptides
C530S320000, C514S002600
Reexamination Certificate
active
06849714
ABSTRACT:
A method of synthesizing a modified therapeutic peptide capable of forming a peptidase-stabilized therapeutic peptide conjugate, the peptide having between 3 and 50 amino acids, is k. In a first step of the method, a therapeutic peptide having a carboxy terminal amino acid and amino terminal amino acid is synthesized. In a second step, pairs of cysteine residues present in the therapeutic peptide are sequentially and selectively oxidized to form disulfide bridges in the therapeutic peptide. In a third step, a protecting group is attached to remaining cysteine residues that do not form disulfide bridges in the therapeutic peptide. Finally, the peptide is coupled to a reactive group capable of reacting with amino groups, hydroxyl groups or thiol groups on a blood component to form a covalent bond therewith.
REFERENCES:
patent: 4462941 (1984-07-01), Lee et al.
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski et al.
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 0 602 290 (1994-04-01), None
patent: 9325217 (1993-12-01), None
patent: 9510302 (1995-04-01), None
patent: 9606626 (1996-03-01), None
patent: 9924075 (1999-05-01), None
patent: 9924462 (1999-05-01), None
patent: 9948536 (1999-09-01), None
patent: 0076550 (2000-12-01), None
patent: 0076551 (2000-12-01), None
C. Knusli et al. Polyethylene glycol (PEG) modification of granulocyte macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity. British Journal of Haematology 1992, 82, 654-663.*
Biotech Report, 1994/1995, 106-107 Patrias, Karen, Pinkus, Anita, McConnell, Harry, Mitchell, Steve.
Proceedings of the 8thAmerican Peptide Symposium, 1983, 409-412 Kenneth Motteson, Nobb RL, Banda PW, Sancles A, Smith AJ.
Int. J. Biochem. Cell. Biol., 1998, 30, 1281-1284 Thim L, Kristensen P, Larsen PJ, Wulff BS.
Endocrinology, 1982, 110 (3), 1049-1051 Reubi JC, Rivier J, Perrin M, Brown M, Vale W.
J. Biol. Chem., 1995, 270 (43), 25344-25347 Kapas S, Catt KJ, Clark AJ.
J. Dev. Physiol., 1989, 12, 55-62 Smith FG, Sato T, Varille VA, Robillard JE.
Anti-Cancer Drugs, 1997, 8, 677-685 Stehle G, Sinn H, Wunder A, Schrenk HH, Schutts, Maier-Borst W, Heene, DL.
Biopolymers (Peptide Science), 1998, 47, 451-463 Oren Z, Shai Y.
Ann. Rev. Neurosci., 1984, 7, 223-255 Akil H, Watson SJ, Young E, Lewis ME, Khachatunan H, Walker JM.
U.S. patent application Ser. No. 09/657,276, Bridon et al.
Chem. Pharm. Bull., 1979, 27 (8), 1942-1944 Hirai Y, Yasuhara T, Yoshida H, Nakajima T, Fujino M, Kitada C.
Proc. Natl. Acad. Sci., 1986, 83, 265-269 Mumby SM, Kahn RA, Manning DR, Gilman AG.
TINS, 1993, 16, 403-409 Selkoe DJ.
U.S. patent application Ser. No. 09/424,571, Ezrin et al., filed Aug. 7, 2003.
U.S. patent application Ser. No. 09/530,891, Blanchard et al., filed Aug. 7, 2003.
Bridon Dominique P.
Ezrin Alan M.
Holmes Darren L.
Milner Peter G.
Thibaudeau Karen
Carlson Karen Cochrane
ConjuChem Inc.
Desai Anand
Morrison & Foerster / LLP
LandOfFree
Protection of endogenous therapeutic peptides from peptidase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection of endogenous therapeutic peptides from peptidase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection of endogenous therapeutic peptides from peptidase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3513161